Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check5 days agoChange DetectedThe page now displays the updated site revision, v3.5.3, replacing the previous v3.5.2; this indicates a software deployment rather than a change to trial information.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange Detected- Revision tag updated from v3.5.0 to v3.5.2. This appears to be a minor maintenance update and does not modify study data or visible content.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible changes to study details or navigation.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded Revision: v3.4.2 and removed notices for Revision: v3.4.1 and a government funding status notice. These are administrative site updates and do not affect the study details on the page.SummaryDifference0.5%

- Check90 days agoChange DetectedA government funding-related notice about potential delays and current operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.